ClinicalTrials.gg
CompletedNCT06633419Updated May 25, 2025

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

A Phase 1 interventional study of Opevesostat and Prednisone in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer.

The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called carbamazepine.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
  • (BMI) ≥18.0 and ≤32.0 kg/m\^2
  • Able to swallow multiple tablets

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History or presence of any of the following:

    • Adrenal insufficiency
    • Hepatic or renal impairment
    • Gallstones, hepatitis disease, or hepatic porphyrias
    • Psychosis
    • hypotension, cardiac arrhythmia, cardiac conduction abnormalities, or recurrent unexplained syncopal events
    • Second- or third-degree atrioventricular heart block
    • Clinically significant sick sinus syndrome
    • Recurrent seizures, increased risk for seizures, or myasthenia gravis
    • Clinically significant hematologic disorders/blood dyscrasias, including adverse hematologic reactions to any drugs or experimental therapies
    • Any systemic fungal infection
    • Chronic infection
    • Glaucoma
    • Hypothyroidism
    • Unexplained electrolyte abnormalities, current hyponatremia, diuretic use, or syndrome of inappropriate antidiuretic hormone secretion (siADH)
    • Severe dermatologic reaction
    • Stomach ulcer
  • Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)
  • History of cancer ()
  • Unable to refrain from or anticipates the use of: Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Opevesostat Period 1

    On Day 1 a single dose of opevesostat will be administered under fasting conditions and a single dose of hormone replacement therapy (HRT) (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after opevesostat dosing.

    Drug: Opevesostat · Drug: Prednisone · Drug: Fludrocortisone acetate

  • Experimental
    Opevesostat Period 2

    There will be a washout of at least 5 days between opevesostat dosing in Period 1 and the first carbamazepine dosing in Period 2. In Period 2, carbamazepine will be administered twice daily (BID) for 17 consecutive days with a single dose of opevesostat coadministered on the morning of Day 14 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions on Day 14, approximately 4.5 hours after opevesostat and/or carbamazepine dosing.

    Drug: Opevesostat · Drug: Prednisone · Drug: Fludrocortisone acetate · Drug: Carbamazepine

Interventions

  • Administered via oral tablet per dosing regimen.

    Also known as: MK-5684, ODM-208

  • Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.

    Also known as: RAYOS®, STERAPRED®, DELTASONE®

  • Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.

    Also known as: FLORINEF®

  • Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).

    Also known as: TEGRETOL®

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostat in plasma

    AUC0-inf of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

  2. Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostat in plasma

    AUC0-last of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

  3. Area under the concentration versus time curve from 0 to hour 24 (AUC0-24) of opevesostat in plasma

    AUC0-24 of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 24 hours post-dose

  4. Maximum concentration (Cmax) of opevesostat in plasma

    Cmax of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

  5. Time to Maximum concentration (Tmax) of opevesostat in plasma

    Tmax of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

  6. Apparent terminal half-life (t1/2) of opevesostat in plasma

    t1/2 of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

  7. Apparent Clearance (CL/F) of opevesostat in plasma

    CL/F of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

  8. Apparent volume of distribution during terminal phase (Vz/F) of opevesostat in plasma

    Vz/F of opevesostat in plasma will be determined.

    Time frame: Predose, and at designated timepoints up to 96 hours post-dose

Secondary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be determined.

    Time frame: Up to approximately 49 days

  2. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue from the study due to an AE will be determined.

    Time frame: Up to approximately 49 days

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Feb 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 9, 2024
StartActual
Dec 18, 2024
Primary completionActual
Feb 12, 2025
CompletionActual
May 13, 2025
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06633419
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Dec 18, 2024
Primary completion
Feb 12, 2025
Completion
May 13, 2025
Last update
May 25, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opevesostat

Start the discussion